top of page
3pexels-dacapture-9739346 copy.jpg

WELCOME TO

GENVARA BIOPHARMA

Our mission is to develop pharmacogenetically-targeted cardiovascular drugs acting through novel mechanisms of action

Genvara’s lead late-stage cardiovascular asset GENCARO
(bucindolol hydrochloride) is a Phase 3-ready, genetically-targeted therapy to treat atrial fibrillation in patients with heart failure.

TM

Asset 11.png

THE SCIENCE and THERAPEUTIC APPLICATION of GENETIC VARIATION

Genvara specializes in identifying common genetic variation that can be therapeutically targeted in cardiovascular disorders. Our basic and clinical research programs focus on human cardiac
systems in order to provide a direct path from discovery to clinical application, utilizing our decades-long experience in molecular genetics, molecular pharmacology, clinical trials and drug
development.

AdobeStock_542825436.jpeg
bottom of page